IVL for Stent Underexpantsion

Medical University of Silesia62 enrolled

Overview

The IVL-Dragon Registry was a multicenter study that enrolled consecutive patients with stent underexpansion treated with IVL in high-volume PCI centers. The primary efficacy endpoint was clinical success, defined as a reduction of stent underexpansion to \<30% with no evidence of in-hospital device-oriented composite end point (DOCE) (defined as a composite of cardiac death, target lesion revascularization, and target vessel myocardial infarction).

Study Type

OBSERVATIONAL

Enrollment

Conditions

In Stent Restenosis Coronary Artery Calcification Intravascular Lithotripsy

Interventions

Percutaneous Coronary InterventionDEVICE

Intravascular lithotripsy (IVL)

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * stent underexpansion treated with intravascular lithotripsy (IVL) Exclusion Criteria: * no

Locations (16)

Department of Invasive Cardiology, Medical University of Bialystok, The Medical University of Bialystok Clinical Hospital

Bialystok, Poland

Outcomes

Primary Outcomes

Clinical Success

Reduction of stent underexpansion to the value of \<30% with no evidence of in-hospital device-oriented composite end point (DOCE)

Time frame: 30 days

Secondary Outcomes

DOCE

composite of cardiac death, target lesion revascularization (TLR), target lesion revascularization, (TLR), and target vessel myocardial infarction (MI)

Time frame: 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.